Jacob Johnson
Stock Analyst at Stephens & Co.
(2.85)
# 1,394
Out of 5,182 analysts
78
Total ratings
45.76%
Success rate
8.57%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $221.80 | +8.21% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $6.74 | -10.98% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $5.02 | +19.52% | 5 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $25.91 | +131.57% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $177.25 | +77.72% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $469.71 | +44.77% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $117.60 | +44.56% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $3.18 | +57.23% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $0.86 | +1,174.33% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $16.18 | +134.86% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $10.59 | +60.53% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $1.98 | +26.26% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $54.19 | +60.56% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $306.16 | +27.38% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $8.29 | +117.13% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $2.62 | +129.01% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $21.38 | +35.64% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $130 | $231.27 | -43.79% | 2 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $169.80 | +122.03% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $221.80
Upside: +8.21%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $6.74
Upside: -10.98%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $5.02
Upside: +19.52%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $25.91
Upside: +131.57%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $177.25
Upside: +77.72%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $469.71
Upside: +44.77%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $117.60
Upside: +44.56%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $3.18
Upside: +57.23%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $0.86
Upside: +1,174.33%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $16.18
Upside: +134.86%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $10.59
Upside: +60.53%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.98
Upside: +26.26%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $54.19
Upside: +60.56%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $306.16
Upside: +27.38%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $8.29
Upside: +117.13%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $2.62
Upside: +129.01%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $21.38
Upside: +35.64%
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $231.27
Upside: -43.79%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $169.80
Upside: +122.03%